

Jean-Louis Excler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5488494/publications.pdf>

Version: 2024-02-01

79
papers

2,600
citations

186265

28
h-index

214800

47
g-index

80
all docs

80
docs citations

80
times ranked

4002
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. <i>Journal of Medical Virology</i> , 2022, 94, 1085-1095.	5.0	34
2	A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td (S	3.8	2
3	The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. <i>Vaccine</i> , 2021, 39, 3067-3080.	3.8	36
4	Vaccine development for emerging infectious diseases. <i>Nature Medicine</i> , 2021, 27, 591-600.	30.7	213
5	Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	1.4	8
6	Supply and delivery of vaccines for global health. <i>Current Opinion in Immunology</i> , 2021, 71, 13-20.	5.5	25
7	Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. <i>Vaccine</i> , 2020, 38, 4476-4483.	3.8	14
8	An overview of Vaxchora TM , a live attenuated oral cholera vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 42-50.	3.3	12
9	Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine. <i>Vaccine</i> , 2020, 38, 1753-1761.	3.8	8
10	Current and future cholera vaccines. <i>Vaccine</i> , 2020, 38, A118-A126.	3.8	57
11	Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. <i>Clinical Infectious Diseases</i> , 2020, 71, S141-S150.	5.8	41
12	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. <i>Vaccine</i> , 2020, 38, 5734-5739.	3.8	6
13	Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. <i>EClinicalMedicine</i> , 2020, 27, 100540.	7.1	14
14	Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. <i>Vaccine</i> , 2020, 38, 7702-7707.	3.8	6
15	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. <i>Vaccine</i> , 2020, 38, 5556-5561.	3.8	9
16	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	4.7	33
17	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
18	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. <i>Vaccine</i> , 2020, 38, 7708-7715.	3.8	4

#	ARTICLE	IF	CITATIONS
19	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
20	Novel prime-boost vaccine strategies against HIV-1. Expert Review of Vaccines, 2019, 18, 765-779.	4.4	34
21	Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990â€™2018. Clinical Infectious Diseases, 2019, 69, S499-S509.	5.8	25
22	Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial. BMC Infectious Diseases, 2019, 19, 422.	2.9	7
23	Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS ONE, 2019, 14, e0211784.	2.5	16
24	The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. Clinical Infectious Diseases, 2019, 69, 877-883.	5.8	122
25	Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. Vaccine, 2019, 37, 5796-5802.	3.8	18
26	Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. Lancet Infectious Diseases, The, 2018, 18, 666-674.	9.1	69
27	Development of Middle East Respiratory Syndrome Coronavirus vaccines â€™ advances and challenges. Human Vaccines and Immunotherapeutics, 2018, 14, 304-313.	3.3	21
28	Molecular epidemiology of a primarily MSM acute HIVâ€™1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia. Journal of the International AIDS Society, 2018, 21, e25204.	3.0	14
29	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS ONE, 2018, 13, e0196397.	2.5	14
30	The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Frontiers in Immunology, 2018, 9, 1397.	4.8	21
31	Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. Vaccine, 2018, 36, 3794-3801.	3.8	36
32	A randomized, observer-blinded, equivalence trial comparing two variations of EuvicholÂ®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines. Vaccine, 2018, 36, 4317-4324.	3.8	8
33	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
34	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Research and Human Retroviruses, 2017, 33, 410-423.	1.1	38
35	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virusâ€™Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Journal of Infectious Diseases, 2017, 215, 95-104.	4.0	38
36	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12

#	ARTICLE	IF	CITATIONS
37	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
38	Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings. Bulletin of the World Health Organization, 2017, 95, 303-312.	3.3	29
39	Accelerating the development of a group A <i>Streptococcus</i> vaccine: an urgent public health need. Clinical and Experimental Vaccine Research, 2016, 5, 101.	2.2	16
40	Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015. Emerging Infectious Diseases, 2016, 22, .	4.3	20
41	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. Journal of Infectious Diseases, 2016, 213, 1946-1954.	4.0	14
42	Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine, 2016, 34, 6610-6616.	3.8	32
43	Lessons from HIV-1 vaccine efficacy trials. Current Opinion in HIV and AIDS, 2016, 11, 607-613.	3.8	21
44	Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS ONE, 2015, 10, e0127998.	2.5	2
45	Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care and STDs, 2015, 29, 389-399.	2.5	54
46	Prospects for a globally effective HIV-1 vaccine. Vaccine, 2015, 33, D4-D12.	3.8	28
47	Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. Human Vaccines and Immunotherapeutics, 2015, 11, 1036-1037.	3.3	6
48	Prospects for a Globally Effective HIV-1 Vaccine. American Journal of Preventive Medicine, 2015, 49, S307-S318.	3.0	29
49	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. Annual Review of Medicine, 2015, 66, 423-437.	12.2	150
50	The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine, 2015, 33, 73-75.	3.8	26
51	HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian Journal of Medical Research, 2015, 142, 633.	1.0	1
52	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2014, 9, e90378.	2.5	13
53	The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Review of Vaccines, 2014, 13, 1489-1500.	4.4	28
54	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. PLoS Pathogens, 2014, 10, e1004543.	4.7	218

#	ARTICLE	IF	CITATIONS
55	HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1734-1746.	3.3	30
56	Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1041-1045.	1.1	3
57	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A33.	1.1	11
58	Nonneutralizing Functional Antibodies: a New "Old" Paradigm for HIV Vaccines. <i>Vaccine Journal</i> , 2014, 21, 1023-1036.	3.1	107
59	HIV Vaccine Efficacy and Immune Correlates of Risk. <i>Current HIV Research</i> , 2014, 11, 450-463.	0.5	13
60	Beyond RV144 Efficacy Results: An Update. <i>Procedia in Vaccinology</i> , 2013, 7, 49-56.	0.4	8
61	Novel directions in HIV-1 vaccines revealed from clinical trials. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 421-431.	3.8	39
62	Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers. <i>PLoS ONE</i> , 2013, 8, e55831.	2.5	41
63	An HIV Vaccine for South-East Asia "Opportunities and Challenges. <i>Vaccines</i> , 2013, 1, 348-366.	4.4	5
64	HIV epidemic in Asia: optimizing and expanding vaccine development. <i>Expert Review of Vaccines</i> , 2012, 11, 805-819.	4.4	10
65	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 630-638.	3.3	4
66	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. <i>PLoS ONE</i> , 2012, 7, e41936.	2.5	74
67	Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens. <i>PLoS ONE</i> , 2012, 7, e45840.	2.5	40
68	AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 669-680.	1.1	28
69	Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors. <i>Hum Vaccin</i> , 2011, 7, 639-645.	2.4	27
70	Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. <i>PLoS ONE</i> , 2011, 6, e27837.	2.5	48
71	HIV vaccines: lessons learned and the way forward. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 428-434.	3.8	118
72	HIV-vaccines: lessons learned and the way forward. <i>Asian Biomedicine</i> , 2010, 4, 683-690.	0.3	0

#	ARTICLE	IF	CITATIONS
73	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1107-1116.	1.1	53
74	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 873-880.	1.1	43
75	A strategy for accelerating the development of preventive AIDS vaccines. <i>Aids</i> , 2007, 21, 2259-2263.	2.2	16
76	AIDS vaccine efficacy trials: expand capacity and prioritize. <i>Expert Review of Vaccines</i> , 2006, 5, 167-170.	4.4	11
77	Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. <i>Lancet, The</i> , 2006, 368, 511-521.	13.7	33
78	Existing cost-effectiveness analyses for diseases caused by Group A Streptococcus: A systematic review to guide future research. <i>Wellcome Open Research</i> , 0, 6, 211.	1.8	2
79	Late Boosting of the RV144 Regimen Improves the Magnitude and Quality of Immune Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0